KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Ionis Pharmaceuticals (IONS) Shares Outstanding (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Shares Outstanding for 18 consecutive years, with $165.9 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding rose 4.31% year-over-year to $165.9 million; the TTM value through Mar 2026 reached $165.9 million, up 4.31%, while the annual FY2025 figure was $163.3 million, 3.42% up from the prior year.
  • Shares Outstanding hit $165.9 million in Q1 2026 for Ionis Pharmaceuticals, up from $163.3 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $165.9 million in Q1 2026 and bottomed at $141.8 million in Q1 2022.
  • Average Shares Outstanding over 5 years is $150.5 million, with a median of $145.8 million recorded in 2024.
  • Year-over-year, Shares Outstanding grew 0.57% in 2022 and then increased 10.06% in 2024.
  • Ionis Pharmaceuticals' Shares Outstanding stood at $142.1 million in 2022, then increased by 1.61% to $144.3 million in 2023, then grew by 9.4% to $157.9 million in 2024, then grew by 3.42% to $163.3 million in 2025, then increased by 1.59% to $165.9 million in 2026.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $165.9 million, $163.3 million, and $161.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.